艾迪注射液联合TP化疗方案治疗中晚期非小细胞肺癌的近期临床观察

目的:观察艾迪注射液联合TP化疗方案治疗中晚期非小细胞肺癌的临床近期疗效和安全性。方法:将我院2007年3月-2011年6月收治的39例中晚期非小细胞肺癌患者随机分为治疗组(23例)和对照组(16例):对照组采用TP方案(紫杉醇175mg.m-2,静脉滴注,d1,顺铂30mg.m-2,静脉滴注,d1～3);治疗组在此基础上加用艾迪注射液(50mL,静脉滴注,d1～14)。2个化疗周期后观察疗效、临床收益及毒性反应。结果:治疗组有效率为52.17%,对照组为43.75%,2组比较差异有统计学意义(P<0.05);治疗组在临床收益上较对照组有所提高(功能状态评分增加>20分的治疗组为60.87%,对照组为43.75%;体重增加>7%的治疗组为56.52%,对照组为37.50%;止痛药用量减少>50%的治疗组为43.48%;对照组为31.25%;疼痛程度降低>50%的治疗组为47.83%,对照组为37.50%),2组比较差异均有统计学意义(P<0.05);治疗组毒性反应较对照组有所减轻(胃肠道反应发生率治疗组为30.43%,对照组为37.50%;白细胞下降发生率治疗组为17.39%,对照组为43.75%;血小板下降发生率治疗组为13.04%,对照组为31.25%),2组比较差异有统计学意义(P<0.05)。结论:艾迪注射液联合TP化疗方案治疗中晚期非小细胞肺癌与单用TP化疗方案比较,能提高近期疗效及改善患者生存质量,同时能减轻毒性反应。

Short-term Clinical Observation of Aidi Injection Combined with TP Chemotherapy for Non small-cell Lung Cancer

OBJECTIVE：To observed the short-term clinical efficacy and safety of Aidi injection combined with TP chemotherapy for medium and advanced non-small-cell lung cancer（NSCLC）.METHODS：39 patients with medium and advanced NSCLC admitted in our hospital during Mar.2007-Jun.2011 were randomized into treatment group（23 cases） and control group（16 cases）.Control group was given TP chemotherapy（paclitaxel 175 mg·m-2,i.v.gtt.d1,cisplatin 30 mg·m-2,i.v.gtt.,d1～3）;treatment group was given Aidi injection（50 mL,i.v.gtt,d1～14） additionally on the basis of treatment for control group.Therapeutic efficacy,clinical profit and toxic reaction were observed after 2 courses of chemotherapy.RESULTS：The effective rate of treatment group was 52.17%,while that of control group was 43.75%,and there was statistical significant difference（P0.05）.The clinical profit of treatment group was improved,compared with control group（KPS score increasing 20 points：treatment group of 60.87%,control group of 43.75%;body weight increasing 7%：treatment group of 56.52%,control group of 37.50%;amount of analgesic agent decreasing 50%：treatment group of 43.48%,control group of 31.25%;pain degree decreasing50%：treatment group of 47.83%,control group of 37.50%）,there was statistical significance in the difference between 2 groups（P0.05）;the toxic reaction of treatment group was relieved,compared with control group（the incidence of gastrointestinal reaction were 30.43% for treatment group and 37.50% for control group;the incidence of leucocytopenia was 17.39% for treatment group and 43.75% for control group;the incidence of thrombocytopenia was 13.04% for treatment group and 31.25% for control group）,there was statistical significance in the difference among 2 groups（P0.05）.CONCLUSION：Compared with TP chemotherapy alone,Aidi injection combined with TP chemotherapy can not only improve short-term efficacy and the life qualities of patients,but also reduce the rate of toxicity reaction.